SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function
Authors
Keywords
-
Journal
Clinical Journal of the American Society of Nephrology
Volume -, Issue -, Pages CJN.11480821
Publisher
American Society of Nephrology (ASN)
Online
2022-03-24
DOI
10.2215/cjn.11480821
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treating Hyperuricemia: The Last Word Hasn’t Been Said Yet
- (2021) Elisa Russo et al. Journal of Clinical Medicine
- SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits
- (2021) Giovanna Leoncini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
- (2020) JingWei Li et al. KIDNEY INTERNATIONAL
- Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
- (2020) Alessandro Doria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Allopurinol on the Progression of Chronic Kidney Disease
- (2020) Sunil V. Badve et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial
- (2020) Austin G. Stack et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD
- (2019) Yuka Sato et al. Nature Reviews Nephrology
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
- (2019) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation
- (2018) Richard J. Johnson et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Association between urinary sodium excretion and uric acid, and its interaction on the risk of prehypertension among Chinese young adults
- (2018) Yang Wang et al. Scientific Reports
- Human Mutations in SLC2A9 (Glut9) Affect Transport Capacity for Urate
- (2018) Anne Ruiz et al. Frontiers in Physiology
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
- (2014) Yukihiro Chino et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Renal Transport of Uric Acid: Evolving Concepts and Uncertainties
- (2012) Ion Alexandru Bobulescu et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- Uric Acid Induces Renal Inflammation via Activating Tubular NF-κB Signaling Pathway
- (2012) Yang Zhou et al. PLoS One
- Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese
- (2009) K Ichida et al. CLINICAL GENETICS
- Plasma Urate Level Is Directly Regulated by a Voltage-driven Urate Efflux Transporter URATv1 (SLC2A9) in Humans
- (2008) Naohiko Anzai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started